Arcellx, Inc. (NASDAQ:ACLX) Insider Christopher Heery Sells 3,456 Shares

Arcellx, Inc. (NASDAQ:ACLXGet Free Report) insider Christopher Heery sold 3,456 shares of the stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $62.29, for a total transaction of $215,274.24. Following the completion of the sale, the insider now owns 36,958 shares in the company, valued at $2,302,113.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Christopher Heery also recently made the following trade(s):

  • On Monday, February 12th, Christopher Heery sold 2,967 shares of Arcellx stock. The stock was sold at an average price of $64.46, for a total transaction of $191,252.82.
  • On Thursday, January 4th, Christopher Heery sold 7,598 shares of Arcellx stock. The stock was sold at an average price of $55.27, for a total transaction of $419,941.46.

Arcellx Stock Down 0.5 %

Shares of ACLX stock opened at $64.57 on Tuesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.84 and a current ratio of 2.84. The firm’s 50-day moving average is $56.69 and its 200-day moving average is $44.89. The stock has a market cap of $3.14 billion, a price-to-earnings ratio of -24.37 and a beta of 0.03. Arcellx, Inc. has a 52-week low of $26.32 and a 52-week high of $67.52.

Arcellx (NASDAQ:ACLXGet Free Report) last issued its earnings results on Monday, November 13th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.25). The firm had revenue of $14.96 million for the quarter, compared to the consensus estimate of $17.15 million. Sell-side analysts predict that Arcellx, Inc. will post -2.47 EPS for the current year.

Institutional Investors Weigh In On Arcellx

A number of institutional investors and hedge funds have recently modified their holdings of ACLX. Suvretta Capital Management LLC grew its stake in Arcellx by 18.8% in the 2nd quarter. Suvretta Capital Management LLC now owns 2,848,167 shares of the company’s stock valued at $90,059,000 after buying an additional 449,846 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Arcellx by 98.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,248 shares of the company’s stock valued at $45,000 after buying an additional 619 shares during the last quarter. Vivo Capital LLC grew its stake in Arcellx by 16.1% in the 3rd quarter. Vivo Capital LLC now owns 503,565 shares of the company’s stock valued at $18,068,000 after buying an additional 69,780 shares during the last quarter. Perceptive Advisors LLC grew its stake in Arcellx by 4.5% in the 2nd quarter. Perceptive Advisors LLC now owns 4,016,397 shares of the company’s stock valued at $126,998,000 after buying an additional 174,658 shares during the last quarter. Finally, Cormorant Asset Management LP grew its stake in Arcellx by 25.0% in the 2nd quarter. Cormorant Asset Management LP now owns 2,000,000 shares of the company’s stock valued at $63,240,000 after buying an additional 400,000 shares during the last quarter.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. Scotiabank assumed coverage on shares of Arcellx in a report on Tuesday, December 19th. They issued a “sector outperform” rating and a $66.00 target price on the stock. UBS Group began coverage on shares of Arcellx in a research note on Tuesday, October 17th. They issued a “buy” rating and a $52.00 target price for the company. TD Cowen started coverage on Arcellx in a research note on Monday, October 30th. They issued an “outperform” rating on the stock. Needham & Company LLC upped their price objective on Arcellx from $65.00 to $71.00 and gave the stock a “buy” rating in a research report on Thursday, January 4th. Finally, HC Wainwright lifted their target price on Arcellx from $50.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday, November 15th. Twelve research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $52.69.

View Our Latest Report on ACLX

About Arcellx

(Get Free Report)

Arcellx, Inc, a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM).

Featured Stories

Insider Buying and Selling by Quarter for Arcellx (NASDAQ:ACLX)

Receive News & Ratings for Arcellx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcellx and related companies with MarketBeat.com's FREE daily email newsletter.